Objective response observed in 21 percent of evaluable patients in the metastatic colorectal cancer (CRC) cohort; reduction in tumor size observed in 54 percent of patients in same cohort<br>Preliminary clinical activity in EGFR-treatment refractory and EGFR-treatment naïve populations, with median progression-free survival of four months in a heavily pre-treated CRC cohort, supports potential for broad clinical effect<br>MM-151 demonstrated an acceptable safety profile in heavily pre-treated patients